Latest news

MEDSIR & DEBIOPHARM Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer

Debiopharm & Repare Therapeutics Announce First Patient Dosed in Phase 1/1B Mythic Trial Evaluating the Synthetic Lethal Combination of WEE1…

Debiopharm to showcase research results of their DDR Inhibitors at the 2024 AACR Conference in San Diego

Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-Driven Solid Tumors

Debiopharm and Repare Therapeutics Partner to Explore the Synthetic Lethal Combination of PKMYT1 and WEE1 Inhibition in Cancer

Debiopharm Shares Oncology Program Updates at ASCO 2023 for Novel WEE1 Inhibitor, and First-In-Class CA IX Theranostic Approach

Debiopharm Launches Phase 1 Research in Small Cell Lung Cancer with WEE1 inhibitor Debio 0123 to Outsmart DDR

Debiopharm Launches Phase 1/2 Combination Trial Investigating Brain-Penetrant Selective WEE1 Inhibitor for Brain Cancer Patients

Debiopharm further explores the potential of its potent, highly selective WEE1 inhibitor Debio 0123 in phase 1 cancer study